Stay updated on MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial
Sign up to get notified when there's something new on the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page.

Latest updates to the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page
- Check4 days agoChange DetectedThe page now presents the ClinicalTrials.gov record for a study of pembrolizumab alone or with copanlisib for relapsed or refractory NK and T-cell lymphoma, including participant criteria, study measures, and record history. It also provides related publications and study documents.SummaryDifference54%

- Check11 days agoChange DetectedThe site revision displayed in the footer changed from v3.7.2 to v3.8.0. The study page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA banner announces an NIH website terminology transition, and the site revision label changes from v3.7.1 to v3.7.2; the page continues to display a 403 error.SummaryDifference1%

- Check39 days agoChange DetectedThe site revision shown in the footer changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page update removes key study documents and record details (examples include Informed Consent Form and Study Protocol), as well as related links and metadata, affecting visibility of consent materials and the study's documentation history.SummaryDifference19%

- Check60 days agoChange DetectedThe page shows a revision tag updated from v3.6.6 to v3.7.0. This indicates a system or content update was applied.SummaryDifference0.1%

Stay in the know with updates to MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-3475 Combo with Copanlisib in NK/T-cell NHL Clinical Trial page.